文献速递核素与放射性配体治疗肿瘤 PET/CT

177Lu-PSMA-617放射性配体治疗转移性去势抵抗性前列腺癌的疗效与安全性

Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
PubMed 文献 · Clin Nucl Med · 2020-01-01

这项前瞻性单臂单中心研究纳入90例经二线内分泌治疗和/或多西他赛化疗后进展的mCRPC患者,评估177Lu-PSMA-617放射性配体治疗的疗效与安全性。结果显示中位总生存期14个月、中位无进展生存期11.8个月,PSA下降>50%者占45.5%(评估结束时),毒性低且短暂,无严重不良事件。

要点

  • 177Lu-PSMA-617治疗mCRPC的中位OS为14个月,中位PFS为11.8个月。
  • 首次治疗后2–3个月PSA下降>50%者占32.2%,评估结束时占45.5%。
  • 放射性相关毒性低且短暂,未观察到严重不良事件。

核心结论

  • 177Lu-PSMA-617放射性核素治疗是mCRPC安全且有效的治疗手段。

研究设计与样本

  • 前瞻性、单臂、单中心研究,纳入90例经二线内分泌治疗和/或多西他赛化疗后进展的mCRPC患者。
  • 主要终点为总生存期,次要终点包括生化反应、无进展生存期、影像学与分子反应、临床反应、安全性及疾病控制率。
  • 除影像学和分子反应在69例患者中评估外,其余终点均在90例患者中评估。

主要发现

  • 患者中位年龄66.5岁(范围30–88岁),每周期中位给药活度为3.7–8 GBq,治疗1–7个周期,中位随访28个月。
  • 首次治疗后2–3个月PSA下降>50%者占32.2%,评估结束时占45.5%。
  • 诊断CT评估的影像学反应:部分缓解23%(16/69)、疾病稳定54%(37/69)、疾病进展23%(16/69),疾病控制率77%。
  • PERCIST 1标准评估的分子肿瘤反应:部分缓解27.5%(19/69)、疾病稳定43.5%(30/69)、疾病进展29%(20/69),疾病控制率71%。
  • 中位总生存期14个月,中位无进展生存期11.8个月;单因素分析未发现与PSA下降相关的变量。

关键数值与推荐

  • 生化反应按前列腺癌工作组3(PCWG3)标准评估。
  • 分子肿瘤反应按实体瘤PET反应标准1(PERCIST 1)评估。
  • 每周期中位给药活度3.7–8 GBq,治疗间隔8–12周,共1–7个周期。

临床怎么用

  • 治疗期间需监测PSA及影像学反应,并按PCWG3和PERCIST标准评估疗效。
  • 该治疗毒性低且短暂,但仍需常规监测不良事件。

局限性

  • 单臂、单中心、前瞻性设计,缺乏对照组。
  • 影像学与分子反应仅在69例患者中评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to evaluate the efficacy and safety of Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC). METHODS: In this prospective, single-arm, single-institutional study, 90 mCRPC patients with progressive disease (PD) on second-line hormonal therapy and/or docetaxel chemotherapy were recruited for the study. All patients underwent diagnostic Ga-PSMA-HBED-CC PET/CT, prior to inclusion for therapy. Included patients underwent Lu-PSMA-617 therapy at 8- to 12-weekly intervals. The primary end point was to assess the overall survival. The secondary and cosecondary end points included biochemical response assessment as per the Prostate Cancer Working Group 3 criteria, progression-free survival, radiological and molecular response criteria, clinical response, safety profile, and disease control rates. All the outcome parameters were evaluated in 90 patients except for the radiographic and molecular response, which was evaluated in 69 patients. RESULTS: The median age of patients was 66.5 years (range, 30-88 years). The median activity administered per cycle was 3.7 to 8 GBq ranging from 1 to 7 cycles, and patients were followed up over a median duration of 28 months. At 2- to 3-month interval after the first therapy and the end of the assessment, greater than 50% decline in prostate-specific antigen was observed in 32.2% and 45.5%, respectively. Univariate analysis did not reveal any variables such as prior therapies, laboratory parameters, concomitant hormonal therapy, and SUV patient parameters associated with prostate-specific antigen decline. Radiographic response by diagnostic CT revealed partial remission in 23% (16/69), stable disease in 54% (37/69), and PD in 23% (16/69) of patients. Molecular tumor response by PET Response Criteria in Solid Tumor 1 criteria revealed 19 (27.5%) of 69 patients with partial remission, 30 (43.5%) of 69 with stable disease, and 20 (29%) of 69 with PD. The disease control rates according to the radiographic and molecular response were 77% and 71%, respectively. The median overall survival and median progression-free survivals were 14 and 11.8 months, respectively. Toxicities related to radioligand therapy were low and transient with no serious adverse effects. CONCLUSIONS: Lu-PSMA-617 radionuclide therapy is a safe and effective approach to the treatment of mCRPC patients.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Yadav MP, Ballal S, Bal C, et al. Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients. Clin Nucl Med. 2020. PMID: 31789908. doi:10.1097/RLU.0000000000002833

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。